埃塞俄比亚及时接种乙肝疫苗出生剂次预防母婴传播的效果
该多中心横断面观察性研究于2022年5月至2024年6月在埃塞俄比亚评估及时接种乙肝疫苗出生剂次(HepB-BD)预防乙肝病毒(HBV)母婴传播(MTCT)的效果。共纳入387名HBV阳性、HIV阴性母亲所生已完成常规乙肝疫苗系列(HepB3)的儿童,结果显示总体MTCT风险为5.2%,单独接种HepB-BD的婴儿MTCT为0%,无出生时免疫预防的婴儿为15.3%,HepB-BD联合乙肝免疫球蛋白(HBIg)的婴儿无传播发生。
要点
- 及时HepB-BD单独或联合HBIg均显示高效预防HBV母婴传播。
- 无出生时免疫预防的婴儿MTCT风险显著增高,且与母亲高病毒载量和HBeAg阳性相关。
- 仅从6周开始的常规乙肝疫苗系列不足以预防HBV母婴传播。
核心结论
- 在埃塞俄比亚,从6周龄开始的常规乙肝疫苗系列不足以预防HBV母婴传播。
- 及时接种HepB-BD在减少HBV母婴传播方面高度有效,应优先在非洲扩大推广。
研究设计与样本
- 多中心横断面观察性研究,于2022年5月至2024年6月在埃塞俄比亚开展。
- 纳入387名HBV阳性、HIV阴性母亲所生且已完成常规乙肝疫苗系列(HepB3)的儿童。
- 在产后6-12个月评估母婴配对HBV母婴传播,并按母亲风险特征(HBV DNA水平、HBeAg状态)分层分析HepB-BD效果。
主要发现
- 婴儿检测中位年龄为10个月(IQR 7.0-11)。
- 总体MTCT风险为5.2%(95% CI 3.4,7.8)。
- 单独接种HepB-BD的婴儿MTCT为0/39(0% [95% CI 0-9.0]),显著低于无出生时免疫预防的婴儿20/131(15.3% [95% CI 10.1-22.4])(p = 0.009)。
- HepB-BD联合HBIg的婴儿无传播发生(0/217,0% [95% CI 0-1.7])。
- 在无出生时免疫预防的婴儿中,母亲病毒载量>200,000 IU/ml(AOR 16.6,95% CI 4.82,57.19)和HBeAg阳性(AOR 4.21,95% CI 1.08,16.44)与MTCT风险增加相关。
临床怎么用
- 在HBV流行区应优先确保新生儿及时接种HepB-BD,以预防母婴传播。
- 对于HBsAg阳性母亲所生婴儿,若条件允许,推荐HepB-BD联合HBIg以获得最大保护效果。
- 应关注母亲高HBV DNA载量和HBeAg阳性状态,这些因素与无出生免疫预防时MTCT风险增加相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mother-to-child transmission (MTCT) is an important route of new hepatitis B virus (HBV) infections. In Africa, limited and conflicting data on the effectiveness of hepatitis B birth dose vaccination (HepB-BD) have contributed to fragmented adoption and sub-optimal implementation. We aimed to assess the effectiveness of timely HepB-BD in preventing HBV MTCT in Ethiopia. METHODS: We conducted a multi-centre cross-sectional observational study in Ethiopia from May 2022 to June 2024. We identified mothers who had tested positive for hepatitis B surface antigen (HBsAg) during pregnancy and assessed mother-infant pairs at 6-12 months post-partum for HBV MTCT. We stratified effectiveness of HepB-BD by maternal risk profile (HBV DNA level, hepatitis B e-antigen (HBeAg) status). RESULTS: The analysis included 387 children born to HBV-positive, HIV-negative mothers who had completed routine HBV vaccination (HepB3). The median age of infant testing was 10 months (IQR 7.0-11). Overall MTCT risk was 5.2% (95% CI 3.4,7.8). MTCT was significantly lower among infants receiving HepB-BD alone (0/39, 0% [95% CI 0-9.0]) compared to those without immunoprophylaxis at birth (20/131, 15.3% [95% CI 10.1-22.4]) (p = 0.009). No transmission occurred with HepB-BD plus HBIg (0/217, 0% [95% CI 0-1.7]). Maternal viral load >200,000 IU/ml (AOR 16.6, 95% CI 4.82,57.19) and HBeAg positivity (AOR 4.21, 95% CI 1.08,16.44) were associated with increased MTCT risk amongst infants without immunoprophylaxis at birth. CONCLUSIONS: In Ethiopia, the current vaccination series starting at 6 weeks is insufficient to prevent HBV MTCT. Timely HepB-BD is highly effective in reducing HBV MTCT and should be prioritised for scale-up in Africa.
引用
- Berhe N, Desalegn H, Mengistu H, et al. Effectiveness of timely hepatitis B birth dose vaccination to prevent mother-to-child transmission in Ethiopia. Clin Infect Dis. 2026. PMID: 42781776. doi:10.1093/cid/ciag598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。